Senseye is developing a diagnostic platform for mental health conditions, with an initial focus on post-traumatic stress disorder (PTSD). The company's technology uses smartphone cameras to analyze ocular biomarkers, measuring disruptions in the sympathetic nervous system through the eyes. This approach enables non-invasive assessments that take under ten minutes to complete, without requiring internet connectivity or specialized equipment. The platform is designed to establish baselines and track clinical outcomes.
The company's technical work spans computer vision, deep learning, and AI-driven diagnostics, with particular expertise in ocular biomarker analysis and autonomic nervous system signal extraction. Over 3,000 patients have been assessed using the platform to date. Senseye has raised over $30 million in funding.
Senseye operates across several industry verticals, including clinical healthcare, pharmaceutical research, military medicine, telehealth, and remote diagnostics.
